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Abstract
Background: Previous studies indicate a role of P2X7 receptors in processes that lead to neuronal death. The main
objective of our study was to examine whether genetic deletion or pharmacological blockade of P2X7 receptors
influenced dopaminergic cell death in various models of Parkinson’s disease (PD).
Results: mRNA encoding P2X7 and P2X4 receptors was up-regulated after treatment of PC12 cells with 1-methyl-4-
phenyl-1,2,3,6- tetrahydropyridine (MPTP). P2X7 antagonists protected against MPTP and rotenone induced toxicity
in the LDH assay, but failed to protect after rotenone treatment in the MTT assay in PC12 cells and in primary
midbrain culture. In vivo MPTP and in vitro rotenone pretreatments increased the mRNA expression of P2X7
receptors in the striatum and substantia nigra of wild-type mice. Basal mRNA expression of P2X4 receptors was
higher in P2X7 knockout mice and was further up-regulated by MPTP treatment. Genetic deletion or
pharmacological inhibition of P2X7 receptors did not change survival rate or depletion of striatal endogenous
dopamine (DA) content after in vivo MPTP or in vitro rotenone treatment. However, depletion of norepinephrine
was significant after MPTP treatment only in P2X7 knockout mice. The basal ATP content was higher in the
substantia nigra of wild-type mice, but the ADP level was lower. Rotenone treatment elicited a similar reduction in
ATP content in the substantia nigra of both genotypes, whereas reduction of ATP was more pronounced after
rotenone treatment in striatal slices of P2X7 deficient mice. Although the endogenous amino acid content
remained unchanged, the level of the endocannabinoid, 2-AG, was elevated by rotenone in the striatum of wild-
type mice, an effect that was absent in mice deficient in P2X7 receptors.
Conclusions: We conclude that P2X7 receptor deficiency or inhibition does not support the survival of
dopaminergic neurons in an in vivo or in vitro models of PD.
Background
The role of extracellular ATP and purinoceptors in neu-
rodegeneration is the focus of a promising area of
research [1-3]. P2X7 receptors belong to the ionotropic
P2X receptors [4], which are sensitive to ATP and other
nucleotides. The homo-oligomeric P2X7 receptor has
distinct structural, functional and pharmacological fea-
tures within the P2X receptor family [2,3,5]: (1) its intra-
cellular carboxy terminal domain is longer than the
other P2X receptor subunits; (2) it has several splice
variants that display distinct functionalities in P2X7
receptor wild-type and knockout mice [6]; (3) its persis-
tent activation elicits the opening of a membrane pore,
which eventually leads to cell death in certain cell types;
and (4) it needs high micromolar concentrations of ATP
to be activated.
P2X7 receptors probably affect neuronal death and
survival in a complex way. An important role of P2X7
receptors in the brain is the modulation of neurotrans-
mitter release [3,7]. The activation of P2X7 receptors eli-
cits Ca
2+ influx, which is followed by increased
glutamate and subsequent GABA release [8-10] that
could reinforce glutamate-mediated excitotoxicity under
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any medium, provided the original work is properly cited.pathological conditions. In addition, P2X7 receptors play
a governing role in the activation and proliferation of
microglia following pathological signals [11,12] and
directly contribute to neurodegeneration by eliciting
microglia-mediated neuronal death [13]. Moreover,
P2X7 receptors are involved in the processing and
release of other key mediators in neurodegeneration,
such as interleukin-1b, [2,14], and in the production of
endocannabinoids, which are neuroprotective. In fact,
P2X7 receptor activation is one of the most powerful sti-
muli that lead to the synthesis and subsequent release of
endocannabinoids from activated microglia [15] and
astrocytes [16].
Accordingly, the blockade or absence of P2X7 recep-
tors were found to be neuroprotective in animal models
of spinal cord injury [17,18], Alzheimer’sd i s e a s e( A D )
[19] and Huntington’s disease [20], but conflicting
results have been found in animal models of ischemia-
reperfusion ([21,22] but see [23,24]) and multiple sclero-
sis ([25] but see [26,27]). However, data regarding P2X7
receptors in the striatum and its role in PD are scarce.
In dopaminergic co-cultures, PCR data indicate the
expression of P2X7 mRNA in neonatal and adult rats
[28], and the presence of P2X7 receptor protein has also
identified in the rat brain striatum and substantia nigra
[29]. Functional P2X7 receptors have been detected in
synaptosomal preparations from the rat midbrain [30]
and in organotypic striatal cultures [31]. In SN4741
dopaminergic cells, ATP-induced swelling and cell death
are reversed by the P2X7 receptor antagonist, KN62, or
by the knock-down of P2X7 receptors with small inter-
fering RNAs [32]. Nevertheless, evidence of a protective
or aggravating role of P2X7 receptors in an in vivo ani-
mal model of PD is still lacking.
This work provides insight on the effect of P2X7
receptor deficiency in different models of PD. The
mRNA encoding P2X7 receptors was up-regulated after
rotenone or MPTP treatment in PC12 cells and in the
striatum, but these changes were not translated to P2X7
receptor protein expression in the striatum. Although
P2X7 receptor antagonists displayed some protective
effect against rotenone-induced toxicity in PC12 cells,
these data could not be replicated in primary dopami-
nergic neurons, in MPTP-induced toxicity or in an in
vitro and an in vivo animal model of PD.
Results
Effect of in vitro MPTP treatment on the expression of
P2X7 and P2X4 receptors
Changes in the levels of mRNA transcripts of the P2X7
and P2X4 receptor subunits were measured using real-
time RT-PCR in PC12 cells after 24 h of a 1 μM in vitro
MPTP treatment (Figures 1A, B). Gene expression level
was normalized to the expression level of the 18S rRNA
reference gene. Quantitative real-time PCR measure-
ments revealed that the mRNA expression of the P2X7
receptor was up-regulated to 2.65 ± 0.55 of the corre-
sponding control values, established as 1 and normalized
to 18S rRNA (Figure 1A; n = 5, P < 0.05). Likewise, the
expression level of the P2X4 receptor was up-regulated
to 1.69 ± 0.22 of the corresponding control values (Fig-
ure 1B; n =5 ,P < 0.05).
Effect of P2X7 receptor antagonists on rotenone and
MPTP-induced inhibition of cell viability in PC12 cells
In conjunction with our previous study [33], treatment
of PC12 cells with the mitochondrial complex I inhibi-
tor, rotenone, elicited a concentration-dependent (0.01-
30 μM) decline in cell viability, measured by the MTT
assay, that resulted in a significant decrease to 79.2 ±
3.7% of the control after a 20 h treatment with a 1 μM
concentration (n = 4, P < 0.01, Figures 1C, E). The same
treatment elevated the amount of released LDH, another
indicator of cellular death, to 169.71 ± 8.91% (n = 4, P <
0.01) (Figure 1G). The treatment of the cells with MPTP
also concentration-dependently (0.01-30 μM) decreased
cell viability in the MTT assay (Figure 1D). The
decrease in cell survival reached a significant level at 10
μM concentration (60.68 ± 1.07%, n = 40, P < 0.01, Fig-
ures 1D, F). This treatment also elicited a significant
increase in the amount of released LDH (137.42 ±
9.08%, n = 8, P < 0.01, Figure 1H). The MAO-B inhibi-
tor, L-deprenyl (10-100 nM), displayed significant pro-
tection against the decrease in cell viability elicited by
rotenone measured either by using the MTT (Figure 1E)
or the LDH assays (Figure 1G). A consistent protective
effect was also observed after MPTP treatment (Figures
1F, H). Pretreatment with the selective P2X7 receptor
antagonists, BBG (10 and 100 nM) and AZ10606120 (10
and 100 nM) had no effect on cell viability after rote-
none treatment when measured with the MTT assay
(Figure 1E). However, identical treatments with the
P2X7 receptor antagonists significantly attenuated the
effect of MPTP in the MTT assay (Figure 1F) and the
effect of both rotenone (Figure 1G) and MPTP (Figure
1H) in the LDH assay.
Effect of P2X7 receptor antagonists on rotenone- and
MPTP-induced inhibition of cell viability in primary
midbrain cultures
Because the molecular machinery of degeneration of
PC12 cells and dopaminergic neurons are not necessa-
rily the same, we next sought to determine how P2X7
receptor antagonists affect cell viability in primary sub-
stantia nigra cultures that contain dopaminergic neu-
rons, which can be identified by tyrosine hydroxylase
immunoreactivity. As shown in Figures 2A-C, MAP2-
positive neurons displayed strong tyrosine hydroxylase
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Figure 1 Effect of P2X7 receptor antagonists on cell viability after rotenone and MPTP pretreatment in PC12 cells. A. and B. Expression
levels of the P2X7 (A) and P2X4 (B) purinergic receptors in PC12 cells after 1 μM MPTP treatment. Quantitative SYBR Green real-time PCR was
performed using specific primers. The experiments were repeated twice with similar results. The expression level of the P2X receptors was
normalized to the expression level of the distinct housekeeping gene, 18S rRNA. Data are displayed as the mean ± S.E.M. Asterisks indicate
significant differences from the corresponding control (*P < 0.05, Student’s t-test). C and D. Concentration-dependent inhibition of cell viability
by rotenone (C) and MPTP (D) in the MTT assay. Cells were treated with various concentrations of the toxins ranging from 0.01 μMt o3 0μM,
and the reduction of MTT into formazan was measured 20 h later. Cell viability is expressed as a percentage of the respective controls. E and F.
Effects of BBG and AZ10606120 on toxicity induced by rotenone (E) and MPTP (F) measured in the MTT assay. Cells were pretreated with L-
deprenyl and with the P2X7 antagonists, BBG and AZ10606120, in 10 and 100 nM concentrations for 1 h before treatment with 1 μM rotenone
or 10 μM MPTP for 20 h. Data are expressed as the percentage of values of control cultures and are the means ± S.E.M. of four experiments. G.
and H. Effects of BBG and AZ10606120 on toxicity induced by rotenone (G) and MPTP (H) measured in the LDH assay. Treatments of the cells
were identical to the MTT assay. The released LDH is expressed as the percentage of total LDH measured after freeze/thaw lysis of cells. These
data are then expressed as the percentage of values of control cultures and are the means ± S.E.M. of four experiments. * P < 0.05, ** P < 0.01,
significance vs. controls using an ANOVA followed by the Dunnett test. E-H. Note that the concentration of rotenone and MPTP are indicated in
μM, whereas the concentration of other drugs in nM.
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Figure 2 Effect of P2X7 receptor antagonists on cell viability after rotenone and MPTP pretreatment in primary substantia nigra (SN)
culture. Non-treated SN cultures contained large tyrosine hydroxylase-positive (arrow) neurons that were identified by MAP2 (red; A) and TH
(green; B) immunoreactivity (merge; C). Rotenone treatment disrupted the neurons (phase contrast morphology; D and MAP2 immunostaining;
E). Scale bar: 20 μm. MAP2+ and TH+ neurons represented 26.28 ± 10.6% and 7.32 ± 2.81% of the total cell number. Total cell number was
determined by counting DAPI-positive nuclei on each of 40 microscopic fields. Cells were counted at 250 × (2 × 10 fields) and 500 × (2 × 10
fields) magnification (independent determinations: n = 4). F. and G. Effects of BBG and AZ10606120 on changes in cell viability induced by
rotenone (F) and MPTP (G) measured in the MTT assay. Cells were pretreated with L-deprenyl and with the P2X7 antagonists, BBG and
AZ10606120, in 10 and 100 nM concentrations for 1 h before treatment with 1 μM rotenone or MPTP for 20 h. Data are expressed as the
percentage of values of control cultures and are the means ± S.E.M. of four experiments. *P < 0.05, ** P < 0.01, significance vs. controls using an
ANOVA followed by the Dunnett test. Note that the concentration of rotenone and MPTP are indicated in μM, whereas the concentration of
other drugs in nM.
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Similar to what we observed in PC12 cells, the treatment
of cultures with rotenone (1 μM) elicited a significant
decline in cell viability when measured in the MTT assay
(78.24 ± 4.15%, n = 7, P = 0.05, Figure 2F). The morpho-
logical destruction of MAP2 neurons was also clearly
observed (Figures 2D, E). Using this model, we did not
observe any protective effect using deprenyl, BBG or
AZ10606120 (Figure 2F). Interestingly, MPTP (1 μM)
caused an elevation of cell viability in these experiments
(136.8 ± 2.49%, n = 7, P < 0.01, Figure 2G), and L-depre-
nyl (10-100 nM), BBG (10 nM) and AZ10606120 (10
nM) attenuated these effects (Figure 2G).
Effect of in vivo MPTP treatment on the expression of
P2X7 and P2X4 purinergic receptors
Similar to what was seen after in vitro MPTP treatment,
the in vivo treatment of WT mice with the dopaminer-
gic neurotoxin, MPTP (4 × 20 mg/kg i.p.), caused an
up-regulation of the mRNA levels of the P2X7 receptor
in the striatum to 3.45 ± 0.95 of the corresponding con-
trol values (Figure 3A, n = 8, P < 0.05). Likewise,
mRNA encoding P2X7 receptor was strongly up-regu-
lated to 8.70 ± 0.34 of the corresponding control values,
established as 1, normalized to 18S rRNA in the sub-
stantia nigra (Figure 3B, n = 4, P < 0.0001). The expres-
sion level of the P2X4 receptor was up-regulated both in
WT and P2X7-/- mice to 2.93 ± 0.6 and 6.42 ± 0.9 of
the corresponding control values (Figure 3C, n = 6, P <
0.05). It is noteworthy that the basal expression of the
P2X4 receptor in P2X7-/- mice was also significantly ele-
vated (3.75 ± 0.8, n = 6, P < 0.05) compared to the
basal expression level of the WT group (Figure 3C).
When the expression of P2X7 receptors in the striatum
was examined at the protein level using a specific anti-
body, a relatively weak P2X7 receptor immunoreactivity
was found in the striatum, in agreement with a previous
study in rats [29]. Punctate immunostaining was
observed throughout the striatum and was co-localized
to microglial cells, which were identified by GSL I - iso-
lectin B4 marker in saline-treated WT mice (Figure 3D).
No apparent change in the expression of P2X7 receptor
was visible in striatal slices derived from WT mice that
had undergone in vivo MPTP treatment; if any, only a
slight decrease in its expression was observed (Figure
3E). The staining intensity of P2X7 receptor immunor-
eactivity was identical with the background in striatal
slices prepared from P2X7-/- mice treated with saline
(Figure 3F).
Effect of in vivo MPTP treatment on biogenic amine
content of the striatum
HPLC analysis of the tissue content of DA and its meta-
b o l i t e s ,D O P A C ,H V A ,n o r epinephrine (NE) and 3-
methoxytyramine (3-MT), and that of serotonin (5-HT)
and 5-hydroxyindoleacetic acid (5-HIAA) showed that,
in saline-treated animals, DA, HVA and 3-MT levels
were significantly higher in mice genetically deficient in
P2X7 receptors compared to WT mice (Figures 4A, B).
We then examined how MPTP treatment (4 x10-20 mg/
kg i.p.) in WT and P2X7-/- mice changed the levels of
these compounds. MPTP caused a dose-dependent and
profound depletion of DA content in the WT group,
which represents a biochemical feature of PD. Similar to
DA, there was a significant decline in the amount of DA
metabolites (e.g., DOPAC, 3-MT) in the WT group, but
no significant decline in the amount of NE was observed
(Figures 4A, B). In the P2X7-/- mice, MPTP treatment
elicited a similar reduction of endogenous DA content
as the WT mice (Figure 4A). Moreover, in the P2X7-/-
group, the reduction of NE, HVA and 3-MT levels after
MPTP treatment was significant, and these changes
were manifest at the lower dose of MPTP treatment
(Figures 4A, B). In contrast, the content of DOPAC did
not change after MPTP treatment in P2X7 receptor defi-
cient animals (Figure 4B). 5-HT and its metabolite (5-
HIAA) were decreased in the WT mice, whereas in the
P2X7-/- group, 5-HT levels were preserved after MPTP
treatment and only 5-HIAA was depleted (Figure 4C).
Treatment with the higher dose (4 × 20 mg/kg) of
MPTP elicited a significant reduction of the survival of
WT mice at the 72 h endpoint of the study (9 out of 16
animals, 56.25%, P < 0.01) compared to saline-treated
animals (13 out of 13 animals, 100%). Genetic deletion
of P2X7 receptors alone did not change mortality in the
saline-treated group (10 out of 10 animals, 100%). A
decrease in survival after MPTP (4 × 20 mg/kg) treat-
ment was also evident in P2X7-/- mice (8 out of 16 ani-
mals, 50%, P = 0.03), but this effect was not significantly
different from the WT group (P > 0.05, Figure 4D). The
lower dose of MPTP treatment (4 × 10 mg/kg i.p.) did
not change the survival rate either in WT (6 out of 6
animals, 100%) or P2X7- / -m i c e( 6o u to f6a n i m a l s ,
100%).
When mice were pretreated with the P2X7 receptor
antagonist BBG in a dose previously shown to be pro-
tective in animal models of HD [20] and spinal cord
injury [17], endogenous DA levels were depleted by
MPTP compared to saline-treated mice (Fig. 4E) similar
to what was observed in mice treated only with MPTP
(Figure 4A). Likewise, a reduction of DOPAC levels was
also observed in mice pretreated with BBG 18 h before
MPTP treatment (Figure 4E).
In vitro rotenone treatment
Striatal slices of WT mice were preincubated in vitro
with the irreversible complex I inhibitor, rotenone (10
μM), for 60 min. Changes in the levels of mRNA
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Figure 3 Changes in the mRNA and protein expression of P2X7 and P2X4 receptors in the striatum and substantia nigra obtained
from P2X7 receptor wild-type (WT) and P2X7-/- (KO) mice after in vivo MPTP treatment. Mice (6-8 mice per group) were injected i.p. with
4 × 20 mg/kg of MPTP or saline (SAL). A-C. After decapitation, the brains were removed immediately, total RNA extracted from the striatum (A,
C) and substantia nigra (B) and then reverse-transcribed to cDNA. Data are displayed as the means ± S.E.M. Asterisks indicate significant
differences from the corresponding saline-injected mice or between genotypes as indicated (*P < 0.05, ***P < 0.0001). D, E. and F.
Immunofluorescent staining for P2X7 receptor and microglial cells in striatal sections of saline- and MPTP-treated WT and P2X7-/- mice. Merged
pictures. Fluorescein-labeled GSL I - isolectin B4 is a marker for endothelial (see stars in picture “F”) and microglial cells. P2X7 receptors were
labeled with a P2X7-DyLight 549 conjugate (red). Orange means the same localization for both stains. DAPI (in Vectashield mounting medium)
labels nuclei (blue). Scale bar: 20 μm. D. Detail of the striatal section of saline-treated WT mouse brain. Inserts (arrows) show the localization of
P2X7 receptors in FITC-labeled microglial cells. E. Only microglial cells are labeled (green, insert, arrow) in the striatal section of MPTP-treated WT
mouse brain. F. Microglia (arrow, insert) and endothelial cells (stars) are labeled by the isolectin, but no P2X7 immunofluorescence is visible in
the striatal sections of saline-treated P2X7-/- mouse brain.
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Figure 4 Effect of genetic deletion and pharmacological antagonists of P2X7 receptors on the level of DA and its metabolites in the
striatum and animal survival after in vivo MPTP treatment. Wild-type (WT) and P2X7 -/- (KO) mice were treated with saline or with MPTP in
doses indicated in the legend (4 × 10-20 mg/kg i. p.) and sacrificed 72 h later. A, B, C and E. Striatal samples were analyzed using HPLC and the
amount of (A, E) dopamine (DA) 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), (B) norepinephrine (NE), 3-methoxityramine
(3-MT) and (C) 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) is expressed in nmol/mg protein (n = 5-8). D. Survival curves of WT and P2X7 -/-
(KO) mice subjected to in vivo MPTP (4 × 20 mg/kg i.p.) treatment (n = 16/group). E. Effect of Brilliant blue G (BBG, 50 mg/kg i.p.) pretreatment
on the level of DA and its metabolites in the striatum of WT mice after in vivo MPTP (4 × 20 mg/kg) treatment. BBG was injected 18 h before
the first MPTP injection. Asterisks indicate significant differences from the corresponding saline-injected mice or between WT and KO mice as
indicated (*P < 0.05, ** P < 0.01, *** P < 0.01).
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measured using real-time RT-PCR. Gene expression
level was normalized to the expression level of the 18S
rRNA reference gene. Quantitative real-time PCR mea-
surements revealed that the mRNA expression of the
P2X7 receptor was up-regulated to 1.42 ± 0.12 of the
corresponding control values (Figure 5A, n = 4, P <
0.05). In contrast, the mRNA level of the P2X4 receptor
showed a decreasing tendency after rotenone treatment
that did not reach the significance threshold (Figure 5A,
0.52 ± 0.26 of the corresponding control values; n = 4,
P > 0.05).
A recent study has shown that, among the ten identi-
fied splice variants of P2X7 receptor subtypes, the P2X7
(k) isoform has fully functional properties that contri-
bute to the diversity of P2X7 receptor signaling in
rodents [6]. We examined the mRNA expression of this
splice variant using RT-PCR in control and 1 μM
MPTP-treated (24 h) PC12 cells and in striatal slices of
WT mice with and without a 10 μM in vitro rotenone
pretreatment (60 min). We used a forward primer speci-
fic for exon 1’ of the P2X7(k) variant with a common
antisense primer in exon 7. The P2X7(k)-specific primer
pairs produced amplicons in both control and rotenone-
treated striatal slices but not in untreated and MPTP-
treated PC12 cells (Figure 5B).
Next, we performed a quantitative identification of the
expression of the P2X7(k) variant mRNA in striatal
slices of WT mice. Real-time PCR analyses revealed that
the mRNA expression of the P2X7(k) variants was
down-regulated to 0.32 ± 0.07 of the corresponding
control values, which were established as 1 and normal-
ized to 18S reference rRNA, in response to a 60-min in
vitro rotenone (10 μM) pretreatment (Figure 5C, n = 3,
P < 0.01).
The basal ATP levels in the substantia nigra were sig-
nificantly higher, but the ADP levels were significantly
lower in WT mice than in the P2X7-/- littermates (Fig-
ures 5D, E). When the substantia nigral preparations,
which contained the cell bodies of dopaminergic neu-
rons that project to the striatum, were preincubated in
vitro with rotenone (10 μM) for 60 min, the ATP con-
tent was significantly decreased in both WT and
P2X7-/- mice (Figure 5D). The same treatment elicited a
significant depletion of ATP content in the striatum of
P2X7-/- but not in WT mice (Figure 5D). This decrease
in ATP content by rotenone was paralleled with an
increase in ADP level in the substantia nigra of WT ani-
mals (Figure 5E), but similar changes were not observed
in the substantia nigra of P2X7-/- animals or in the
striatum of either genotype (Figure 5E). AMP levels and
the energy charge (EC) were not significantly altered in
the substantia nigra and the striatum either by genetic
deletion of P2X7 receptors or rotenone treatment (Fig-
ures 5F-G).
Rotenone treatment depleted striatal DA content in
both WT and P2X7-/- mice, and the amount of DA
metabolite DOPAC was significantly increased in the
P2X7-/- group compared to saline treatment (P < 0.05,
P < 0.01, Figure 6A). In slices derived from P2X7-/-
mice, rotenone treatment also depleted the NE content
(P < 0.01, Figure 7B). The amounts of 3-MT, 5-HT and
5-HIAA were insignificantly changed either by rotenone
treatment or by the genetic deletion of P2X7 receptors
(Figures 6B, C).
After loading striatal slices with [
3H]DA, radioactivity
uptake was 55996 ± 9346 Bq/g (n = 8) in WT mice and
71115 ± 15573 Bq/g (n = 4) in P2X7-/- mice, which
were not significantly different from each other (P
>0.05). Low frequency EFS (25 V, 2 Hz, 240 shocks) was
used to mimic neuronal activity. This stimulation eli-
cited a rapid and reproducible efflux of [
3H]DA in stria-
tal slices obtained from the WT and P2X7-/- groups
(Figure 7A). Rotenone treatment did not change radio-
activity uptake in the WT group (96084 ± 26879 Bq/g,
n=4 ;P >0 . 0 5 )a n di nt h eP 2 X 7-/- group (42072 ±
6569 Bq/g, n = 8; P > 0.05), whereas electrical field sti-
mulation evoked [
3H]DA release also remained
unchanged in WT and P2X7-/- mice (Figure 7B). These
results imply that, despite the considerable depletion of
endogenous DA content, striatal slices accumulate and
release exogenous dopamine after rotenone treatment in
response to neuronal activity, and the genetic deletion
of P2X7 receptors did not alter this ability of dopami-
nergic nerve terminals.
The levels of the excitatory amino acids, glutamate
and aspartate, and of the inhibitory amino acid, GABA,
in the striatum did not change following in vitro rote-
none treatment and was similar in WT and P2X7-/- ani-
mals (Figure 7C). In contrast, the content of the
endocannabinoid, 2-arachidonoyl glycerol (2-AG), but
not anandamide (AEA), was markedly elevated after
rotenone treatment in the WT mice (Figure 7D).
Although rotenone treatment also tended to increase 2-
AG levels in the P2X7-/- mice, the elevation was much
l o w e rt h a ni nt h ep r e s e n c eo fP 2 X 7 receptors (Figure
7D).
Discussion
The main objective of our study was to examine the role
of the P2X7 receptor in various PD models. We demon-
strated that the mRNA encoding the P2X7 receptor was
up-regulated in animal models of PD. However, our
results conflict with the concept that treatment with
P2X7 receptor antagonists can alleviate the progress of
PD.
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Figure 5 The effect of in vitro rotenone pretreatment on the mRNA expression of P2X7 and P2X4 receptors and the P2X7 (k) splice
variant, ATP, ADP and AMP contents and on the energy charge in the substantia nigra and striatal slices of wild-type (WT) and P2X7
receptor knockout (KO) mice. Striatal slices were preincubated with in vitro rotenone (10 μM) for 60 min. (A) Quantitative SYBR Green real-time
PCR was performed using specific primers. The experiments were repeated twice with similar results. The expression level of the P2X receptors
was normalized to the expression level of the distinct housekeeping gene, 18S rRNA. Data are displayed as the means ± S.E.M. Asterisks indicate
significant differences from the corresponding control (*P < 0.05, Student’s t-test). B. Confirmation of the expression of the P2X7(k) variant using
RT-PCR with specific forward primers for P2X7(k) isoforms and a common reverse primer. RT-PCR analysis showed that P2X7(k)-specific primer
pairs produced amplicons are present in striatal slices. The gel is 1.5%, 1× TBE buffer. A 100-bp DNA ladder (Fermentas, Vilnius, Lithuania) was
used to identify PCR fragment sizes, and the amplification of 18s RNA was used as an internal control. C. Changes in mRNA expression levels of
P2X7(k) variant in the striatum obtained from P2X7 receptor wild-type mice after in vitro rotenone pretreatment. Quantitative SYBR Green real-
time PCR was performed using specific primers. The experiments were repeated twice with similar results. The expression level of the P2X7(k)
isoform was normalized to the expression level of the distinct housekeeping gene 18S rRNA. Data are displayed as the means ± S.E.M. Asterisks
indicate significant differences from the corresponding control (**P < 0.01, Student’s t-test). D, E, F. Tissue contents of ATP, ADP and AMP,
expressed in nmol/mg protein (n = 5-8). G. For the calculation of energy charge (EC) see Materials and Methods. * P < 0.05, ** P < 0.01,
significance vs. control.
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Page 9 of 18In agreement with previous studies [33-35], rotenone
treatment elicited a concentration-dependent decline in
cell viability of PC12 cells and primary dopaminergic
neurons, as measured using the MTT and LDH assays.
This effect was also obvious in morphological signs and
was significantly reversed by the antiparkinsonian drug,
L-deprenyl. MPTP also decreased cell viability in PC12
cells in a concentration-dependent and deprenyl-sensi-
tive manner, as measured with the MTT assay, and
caused an increase the amount or released LDH in 10
μM concentration. However, a lower concentration (1
μM) of MPTP, did not elicit significant effect in PC12
cells and even increased cell viability in primary dopami-
nergic neurons. This latter finding is not surprising,
however, because a transient proliferative effect of
MPTP has been reported in PC12 cells after a 24 h
incubation, which is dependent on the MEK1 pathway
[36].
We used two P2X7 receptor antagonists in this model,
BBG, which is selective for P2X7 receptors in the con-
centrations used here [37], and AZ10606120, which is a
potent negative allosteric modulator of P2X7 receptors
with a nanomolar IC50 value [38]. Both compounds
were found to confer protection against MPTP treat-
ment in both MTT and LDH assays and against rote-
none-induced decrease in cell viability of PC12 cells
when viability was measured using the LDH assay.
Because the stimulation of P2X7 receptors leads to cell
death in different cell types [32,39], these results imply
that P2X7 receptors were endogenously activated by the
released ATP, and thereby contributed to toxicity eli-
cited by mitochondrial toxins.
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Page 10 of 18In contrast, we could not detect a protective effect
against rotenone of either BBG or AZ10606120, when
cell viability was measured using the MTT assay in
PC12 cells, and when primary midbrain culture was
assessed. PC12 is a pheochromocytoma cell line able to
synthesize catecholamines, whereas primary midbrain
culture is a mixed population consisting of glia and
MAP
+ neurons, including TH
+ immunopositive dopami-
nergic neurons. Therefore, one possible explanation to
the lack of protective effect of P2X7 receptor antagonists
in the primary culture is the presence of glia, which also
express P2X7 receptors and, which might also influence
the process leading to neuronal death. This assumption
is supported by further observations of the present
study using in vivo MPTP treatment and in vitro striatal
slices. In fact we could not detect protective effect of
genetic deletion of P2X7 receptors in those PD models,
where the synaptic organization and its environment
provided by the glia was retained.
The up-regulation of P2X7 and P2X4 receptors at the
mRNA level was also observed in the substantia nigra
and striatum after the in vivo treatment with the dopa-
minergic neurotoxin, MPTP. To examine whether these
changes were also translated to protein synthesis, we
examined the distribution of P2X7 receptor immunor-
eactivity in the striatum in saline- and MPTP-treated
WT mice. As expected, P2X7 receptor immunofluores-
cence was localized to microglia in the striatum of WT
mice. However, no visible change in P2X7 receptor
immunostaining was observed after in vivo MPTP treat-
ment. This result is in agreement with the findings of
Amadio et al. [29], who found an unchanged P2X7 pro-
tein level after 6-OHDA denervation in the rat striatum.
Although the precise cell type specific localization of
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Figure 7 The effect of in vitro rotenone pretreatment on EFS-evoked [
3H]DA release and on the levels of glutamate (Glu), aspartate
(Asp), GABA and of the endocannabinoid 2-AG and anandamide (AEA) in wild-type (WT) and P2X7 receptor knockout (KO) mice.A ,B .
Slices were perfused with Krebs solution and subjected to electrical field stimulation (25 V, 1 msec, 2 Hz, 240 shocks) during the 3
rd and 13
th
sample collection period (S1, S2) after a 60-min preincubation with rotenone (10 μM, B) or Krebs’ solution (A). [
3H]DA release is expressed as
fractional release (FR%, for calculation see Materials and methods) as a function of time (n = 5-8). C, D. Samples were analyzed using HPLC, and
the results are expressed in nmol/mg protein (C) or in pmol/mg protein (D) (n = 5-8). Asterisks indicate significant differences from the
corresponding control or between WT and KO mice as indicated (** P < 0.01).
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ings imply that activity-dependent changes in the level
of mRNA encoding P2X7 receptors is not accompanied
with similar changes in protein synthesis, or that they
are compensated by counter-regulatory events.
When mice were pretreated in vivo with MPTP, a
dose-dependent and severe depletion of endogenous DA
in the striatum was observed as a consequence of the
ongoing degeneration of dopaminergic nerve terminals.
Although basal dopamine levels were higher in the
striata of P2X7-/- mice, MPTP treatment elicited a simi-
lar reduction in DA content in the WT mice. Moreover,
after the genetic deletion of this receptor subtype, a
reduction in NE content was also manifest at the lower
dose of MPTP treatment. This result indicates an exten-
sion of neurodegeneration in the absence of P2X7 recep-
tors, although endogenous 5-HT levels were relatively
preserved. To test the effect of the pharmacological
inhibition of P2X7 receptors, we utilized BBG, a P2X7
receptor antagonist that penetrates the blood brain bar-
rier, and is efficacious in animal models of spinal cord
injury [17,18] as well as Huntington’s disease [20] in the
dose applied. Nevertheless, treatment with BBG did not
afford neuroprotection in our hands, at least using an
acute treatment protocol.
It has been established previously that the pathological
hallmarks of PD can be reproduced in vivo with the
sub-chronic application of the irreversible mitochondrial
complex I inhibitor, rotenone [40-42], or with the in
vitro pretreatment of striatal slices with rotenone [33] in
rats. Our findings in mice confirm and extend these
data, i.e., the depletion of endogenous DA levels in the
striatum concomitant with a decrease in endogenous
ATP levels in the striatum and substantia nigra. Inter-
estingly, a more pronounced ATP depletion was found
in the substantia nigra than in the striatum after rote-
none treatment, which corroborates with the well-
known vulnerability of this brain area to mitochondrial
toxins. Similar to the results seen after in vivo MPTP
treatment however, genetic deletion of P2X7 receptors
did not reverse these changes but exacerbated the
d a m a g ea n de l i c i t e daf u r t h e rd r o po fe n d o g e n o u sA T P
and NE contents. Moreover, basal ATP levels were sub-
stantially lower in the substantia nigra of P2X7-/- mice.
Taken together, P2X7 receptor deficiency did not ame-
liorate the effects of dopaminergic neurotoxins, rather
these effects were potentiated.
Although these findings are somewhat unexpected in
light of the regulation of excitotoxic and neuroinflam-
matory pathways by P2X7 receptors [2,3,43,44], there
are several explanations for the lack of neuroprotection
following genetic deletion and pharmacological antagon-
ism of P2X7 receptors.
It is well known that results generated using knock-
out mice must be treated with caution because compen-
satory mechanisms may occur. Our results clearly
demonstrated that mRNA encoding the P2X4 receptor
was up-regulated in the striatum of P2X7-/- mice com-
pared to the WT group, and the expression levels of the
P2X7 and P2X4 receptors were similarly elevated after
MPTP treatment in PC12 cells. However, a similar
change in P2X4 mRNA level was not observed in the
rotenone-treated striatum. P2X4 and P2X7 receptors are
frequently co-expressed [4] in particular on microglia,
which is the cell type that governs neuroinflammation.
Weinhold et al. [45] found that in alveolar epithelial
cells, the expression of P2X4 receptors was strongly
increased after P2X7 down-regulation, which indicates
crosstalk and feedback signaling between these two
receptors. Taking into account that the affinity of ATP
for P2X4 receptors is much higher than for P2X7 recep-
tors [5], the P2X4 receptor is a strong candidate to com-
pensate the actions mediated by P2X7 receptors in cases
of genetic deletion or pharmacological blockade.
Another possible interpretation of the lack of neuro-
protection following the deletion of P2X7 receptors is
the existence of splice variants, which partly retain their
functionality in the CNS in different P2X7 knockout
mice lines [6]. So far ten splice variants of the P2X7
receptor (P2X7(b) through P2X7(k)) have been described
[6,46,47]. However, out of them only one, the recently
identified P2X7(k) [6] has been found to be fully func-
tional. Therefore, we have examined the mRNA expres-
s i o no ft h i sv a r i a n ti nP C 1 2c e l l sa n di nt h er o t e n o n e
treated rat striatum. The transcript encoding the P2X7
(k) variant was expressed in the WT striatum, but its
expression level was decreased after rotenone treatment,
which does not support its involvement as a compensa-
tory receptor.
A third, most intriguing possibility is that that activa-
tion of P2X7 receptors may also mediate neuroprotective
effects, which could counterbalance its deleterious
actions. The activation of P2X7 receptors in astrocytes
enhances P2Y2 mRNA expression [48], which can trig-
ger neuroprotective pathways through the induction of
genes for anti-apoptotic factors, neurotrophins, growth
factors and neuropeptides [49]. Moreover, recent studies
have shown that the P2X7 nucleotide receptor is
coupled to GSK-3 inhibition and confers neuroprotec-
tion in cerebellar granule neurons [50,51]. P2X7 recep-
tors also play important roles in the synthesis and
subsequent release of endocannabinoids from activated
microglia and astrocytes [15,16]. The activation of CB1
and CB2 receptors by endocannabinoids mediates neu-
roprotection in different pathological models [52-54],
including animal models of PD [55,56]. Our data
Hracskó et al. Molecular Neurodegeneration 2011, 6:28
http://www.molecularneurodegeneration.com/content/6/1/28
Page 12 of 18indicate that this endogenous protective mechanism was
activated after an in vitro rotenone treatment because
an increased level of 2-AG was detected in the striatum.
In contrast, elevation of 2-AG levels was absent in the
striatum of P2X7-/- mice, which may lead to the allevia-
tion of the 2-AG-mediated neuroprotective action.
Finally, an important factor that might influence
whether beneficial or deleterious actions mediated by
P2X7 receptors predominate, is the age of animals. In
support of this idea, Jimenez et al. [57] found that at
early ages (4-6 months), activated microglia are
restricted to amyloid deposits and are characterized by
the absence of cytotoxic factors using a transgenic
mouse model of Alzheimer’s disease. In contrast, at
older ages, microglial activation shows a classic pheno-
type with the production of cytotoxic factors. Taking
into account the governing role of P2X7 receptors in the
activation and proliferation of microglia and in micro-
glia-mediated death of neurons [2,12], the relatively
young age of the mice used in our experiments may
also explain the lack of protection by P2X7 inhibition.
Conclusions
The results of experiments in different PD models do
not indicate a consistent protective effect of deficiency
or inhibition of the purinergic receptor subtype P2X7.
Moreover, certain neurochemical alterations characteris-
tic to PD were exacerbated after MPTP or rotenone
treatment in P2X7 deficient mice, with a concomitant
decline in the accumulation of the neuroprotective
endocannabinoid 2-AG. We conclude that P2X7 recep-
tor deficiency or inhibition does not promote the survi-
val of dopaminergic neurons in an in vivo or in vitro
models of PD and supports the view that P2X7 receptors
play a double-faced role in different cellular cascades
that lead to neuronal death.
Methods
Animals
All studies were conducted in accordance with the prin-
ciples and procedures outlined in the NIH Guide for the
Care and Use of Laboratory animals and were approved
by the local Animal Care Committee of the Institute of
Experimental Medicine (Budapest, Hungary, ref. No.
22.1/3671/003/2008). Two to 3-month old male wild-
type (WT) and P2X7 receptor knockout mice (P2X7−/−)
were housed in a light- (12 h on, 12 h off) and tempera-
ture-controlled room with food and water available ad
libitum. All experiments were performed during the
light phase between 7:30 am and 3:30 pm. Homozygous
P2X7 receptor WT mice were bred on a background of
C57Bl/6J. The original breeding pairs of P2X7R−/− mice
were kindly supplied by Christopher Gabel from Pfizer,
Inc. (Groton CT, USA). The animals contained the
DNA construct P2X7-F1 (5’-CGGCGTGCGTTTTGA-
CATCCT-3’)a n dP 2 X 7-R2 (5’-AGGGCCCTGCG-
GTTCTC-3’), previously shown to delete the P2X7
receptor [58]. Genomic DNA was isolated from the tails
of WT and P2X7−/− animals, and the genotypes were
confirmed by PCR analysis. Animals were randomly
assigned to experimental clusters of 6-8 mice in each
group. All animals were given intraperitoneal (i.p.) injec-
tions of sterile saline (0.9% NaCl) or 4 × 10-20 mg/kg
MPTP, separated by 2 h. Treatment with the P2X7
receptor antagonist, Brilliant blue G (BBG, 50 mg/kg i.
p), was administered 18 h before the first MPTP injec-
tion. Mice were euthanized by decapitation 72 h after
the last treatment. The striatum was collected, frozen
on dry ice and stored at −70°C until homogenization.
Other mice were treated in vitro. After decapitation, the
striatum was removed and sliced into 400- μm-thick
sections, and the slices were incubated with 10 μM rote-
none for 60 min in Krebs’ solution kept at 37°C and
bubbled with a mixture of 95% O2 +5 %C O 2 (see
below).
Cell culture
PC12 cells
PC12 cells were grown in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% heat-inactivated fetal
bovine serum. The cultures were maintained in a humi-
dified atmosphere containing 5% CO2 at 37°C. For
experiments assessing the effect of drugs on rotenone-
or MPTP-induced cell death, PC12 cells were seeded on
96-well plates in a density of 5000 cells/well, preincu-
bated with 10 and 100 nM of L-deprenyl, AZ10606120
or BBG for 1 h and then treated with rotenone (0.01-30
μM) or MPTP (0.01-30 μM). The incubation was then
continued for 20 h at 37°C.
Cultures of ventral midbrain cells
Timed pregnant C57BL/6 mice were deeply anesthetized
with an i.p injection of a xylazine-ketamine mixture on
days 12-13.5 after vaginal plug identification. The
embryos (E12 - E13.5) were aseptically dissected and
rinsed with a Ca
2+-free PBS (pH 7.4) containing 40 μg/
ml gentamicin (Sanofi-Aventis) and 250 μg/ml fungi-
zone (Sigma, Hungary). The brains were rapidly
removed and the ventral mesencephali were dissected.
Tissue pieces were incubated in a trypsin solution (0.5%
trypsin (w/v; Sigma, Hungary) in PBS containing 50 μg/
ml DNAse I (Sigma, Hungary) for 20 min at room tem-
perature. After incubation, the tissue pieces were trans-
ferred onto a nylon mesh (pore diameter 43 μm) fixed
to the bottom of a polypropylene tube and triturated
within the tube in 10% FCS in Minimum Essential Med-
ium (MEM-FCS) (Sigma, Hungary) using a Pasteur pip-
ette. The suspension of single cells streamed through
the mesh was collected (approx. 2 ml/embryo). After
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MEM-FCS onto poly-L-lysine coated 96-well culture
plates (105 cells/100 μl/well; Falcon; BD) or onto poly-
L-lysine coated glass cover slips (d = 12 mm; 5 × 105/
500 μl/well) in 4-well plates. After adhesion of cells, the
medium was changed and the cells were maintained in
DMEM/F12 (1/1) supplemented with B27 (Invitrogen).
The medium was changed every second day and was
supplemented with 20 ng/ml BDNF (Invitrogen) from
the second day. Cultures were treated on days 6-7 in
vitro with L-deprenyl, AZ10606120 or BBG and then
with 1 μM rotenone or 1 μM MPTP as described above.
Quantitative real-time PCR experiments
The striata and the PC12 cells were lysed and homoge-
nized in Trizol. Total RNA was isolated from the cell
lysates using the RNeasy Lipid Tissue Mini Kit (Qiagen)
according to the manufacturer’si n s t r u c t i o n s .T h ep u r i -
fied RNA was reverse-transcribed with a RevertAid First
Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithua-
nia) as described in our previous study [59]. Briefly, the
cDNA samples were prepared by reverse transcribing 2
μgo ft o t a lR N Au s i n g1μlo fR e v e r t A i dHM i n u sM -
MuLV reverse transcriptase in a mixture containing 5 μl
of 5× reaction buffer, 1 μl random hexamer primer (10
pmol/μl), 1 μl of RiboLock™ RNase Inhibitor (20 u/μl)
and 2 μlo f1 0m Md N T Pm i x ,w h i c hw a sb r o u g h tu p
to a final volume of 20 μl with 0.1% diethylpyrocarbo-
nate-treated distilled water. The reverse-transcription
reaction was performed at 70°C for 5 min and was fol-
lowed by incubation at 25°C for 5 min. The synthesis
was continued for 10 min at 25°C and was followed by
60 min at 42°C. The samples were finally stored at −20°
C. The expression levels of the target genes were deter-
mined from the cDNA samples using quantitative real-
time PCR (Rotor-Gene 3000; Corbett Research, Sydney,
Australia). Real-time PCR was performed according to
standard protocols using the LightCycler DNA Master
SYBR Green I Kit (Roche, Indianapolis, IN, USA). PCR
conditions were optimized for primers, templates and
MgCl2. The PCR cycling protocol was set to the follow-
ing parameters: initial denaturation, 95°C for 10 min;
cycling, 95°C for 20 s, 59°C for 20 s, 72°C for 20 s; 45
cycles. All PCR primers were based on a previous study
[60] with the following sequences: P2X4 receptor for-
ward: 5’-ATC GTC ACC GTG AAC CAG ACA CA,
reverse: 3’-CCA CGA TTG TGC CAA GAC GGA AT
P2X7 receptor forward: 5’-CCA CAA CTA CAC CAC
GAG AAA C, reverse: 3’-ACT TCT TGG CCC TTG
ACA TCT T; 18S forward: 5’-GTA ACC CGT TGA
ACC CCA TT, reverse: 3’-CCA TCC AAT CGG TAG
TAG CG. Primers for the amplification of the P2X7(k)
variant cDNAs were based on the study of Nicke et al.
[6] and were the following: P2X7 receptor 1’ exon-
specific forward primer 5’ GCC CGT GAG CCA CTT
ATG C-3’ and reverse primer in exon 7 5’-TCT GTA
AAG TTC TCT CCT GC-3’. The conditions for amplifi-
cation in this case were as follows: 95°C for 10 min,
initial denaturation at 94°C for 30 s, 59°C for 30 s, and
72°C for 30 s for 45 cycles with a final extension at 72°C
for 7 min. To ensure the specificity of the reaction and
accurate quantification, a melting curve analysis was
performed after each reaction, which confirmed the lack
of primer-dimer artifacts or contamination in all cases.
All ΔCt values were calculated using the Rotor-Gene 6
software (Corbett Research, Sydney, Australia). Expres-
sion levels of the target genes were normalized to the
reference gene, 18S rRNA. The target gene and the
reference gene were measured together within the same
experiment. To compare the expression levels of target
genes between different experimental groups, the effi-
ciency calibrated model of Pfaffl [61] was applied. Dif-
ferences in gene expression were considered significant
when the P level was < 0.05. Data are presented as the
mean normalized expression ratio ± SEM.
RT-PCR amplification of P2X7(k) variant mRNAs
The striata and the PC12 cells were lysed and homoge-
nized in Trizol. Total RNA samples were isolated and
purified from the cell lysates using the RNeasy Lipid
Tissue Mini Kit (Qiagen) according to the manufac-
turer’si n s t r u c t i o n s .R N A( 2μl) was reverse-transcribed
with the RevertAid First Strand cDNA Synthesis Kit
(Fermentas, Vilnius, Lithuania) as described in our pre-
vious study [59]. Primers for amplification of the P2X7
(k) variant cDNAs were subjected to RT-PCR amplifica-
tion under the following conditions: 35 cycles, initial
denaturation at 94°C for 30 s, 59°C for 30 s, and 72°C
for 30 s for 35 cycles with a final extension at 72°C for
7 min.
Fluorescence microscopy
Primary cultures grown on microscopic cover slips for 8
days were rinsed with PBS and fixed in 4% paraformal-
dehyde (w/v in PBS) for 40 min at room temperature.
After washing with PBS, the cultures were treated with
0.1% TritonX100 in PBS for 5 min and non-specific
binding sites were blocked by a 2-hour incubation with
3% donkey and normal horse sera (Jackson ImmunoRe-
search Europe Ltd. Newmarket, Suffolk, UK) in 0.1 M
phosphate buffer (PB, pH 7.4). Cells were incubated
with a mixture of MAP2 (1:1000; polyclonal rabbit;
Abcam, Cambridge, UK) and tyrosine hydroxylase
(1:500; monoclonal mouse; Chemicon, Billerica, MA,
USA) primary antibodies at 4°C overnight. For control
experiments, the primary antibodies were omitted. Bioti-
nylated anti-mouse IgG (Vector Laboratories; Burlin-
game, CA, USA) and Alexa Fluor 594-conjugated anti-
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applied as secondary antibodies for 2 h at room tem-
perature. Streptavidin-FITC (1:1000) in PB was applied
for 2 h. Stained cultures were mounted in Mowiol 4-88
(Polysciensce Inc, Warrington, PA, US) containing
Hoechst nuclear dye and investigated with an Axiovert
2 0 0Mm i c r o s c o p ea n dt h eA x i o V i s i o n4 . 8p r o g r a m
(Zeiss, Jena Germany).
Laser scanning confocal microscopy for the investigation
of P2X7 receptor localization in striatal sections
After removing the brain, the striatum was removed and
fixed for 2 × 1 h in 4% paraformaldehyde in 0.1 M
phosphate-buffered saline (pH 7.4). Thirty-micron sec-
tions were cut using a vibrating microtome (VT1000S;
Leica Microsystems, Milton Keynes, UK). The sections
were washed, kept in 0.1 M phosphate-buffered saline
and then transferred to 30% sucrose in PBS at 4°C until
they sank. Freeze-thawing in liquid nitrogen was applied
to increase the penetration of the antisera used for
immunostaining. The sections were incubated first in
the mixture of 3-3% donkey and normal horse sera
(Jackson ImmunoResearch Europe Ltd. Newmarket, Suf-
folk, UK) in 0.1 M phosphate buffer pH 7.4 for 2 h, and
then in the 1:200 dilution of the P2X7 polyclonal anti-
body (Santa Cruz Biotechnology, Inc. Santa Cruz, CA,
USA) overnight at 4°C. After thorough washing, fluores-
cein-labeled GSL I - isolectin B4 (Vector Laboratories;
Burlingame, CA, USA) in a 1:100 dilution and 1:400
DyLight 549 AffiniPure Donkey Anti-Goat IgG (Jackson
ImmunoResearch) were applied overnight. Sections
incubated without primary antibodies served as controls.
After final washes in PBS, the sections were transferred
onto microscopic slides and mounted in Vectashield
(Vector Laboratories; Burlingame, CA, USA). Confocal
microscopic images were scanned with a Nikon A1R
microscope equipped with NIS-Elements C software.
Images were edited and the brightness and contrast
were adjusted if necessary using Adobe Photoshop CS3
(San Jose, CA, USA).
Cell viability assays
Cell viability was assessed using the colorimetric
reagent, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetra-
zolium bromide (MTT). A stock solution of the dye was
prepared, filter-sterilized and stored at -20°C. After
MPTP or rotenone treatment in 96-well plates, 5 mg/ml
MTT was added to each well, and the incubation was
continued for another 4 h. The converted dye was solu-
bilized with acidic isopropanol (0.04 M HCl in absolute
isopropanol). Reduced MTT was measured at a wave-
length of 570 nm.
As another indicator of cell viability, lactate dehydro-
genase (LDH, E.C. 1.1.1.27) was also assayed in
experiments performed on PC12 cells. LDH activity that
had been released into the media was evaluated using
the CytoTox96 nonradioactive assay kit (Promega,
Madison, WI, USA) according to the manufacturer’s
instructions. The LDH activity was quantified by mea-
suring the wavelength absorbance at 490 nm with a Per-
kin-Elmer 1420 Multilabel counter. The released LDH
activity is expressed as a percentage of total LDH activ-
ity, which was determined after freeze-thaw lysing of the
cells.
HPLC determination of adenine nucleotides, monoamines,
amino acids and endocannabinoids
Animals were sacrificed by decapitation, and the stria-
tum or the substantia nigra was dissected on ice under
a stereomicroscope. In the case of in vivo MPTP-treated
animals, after the preparation of the striatum, the native
tissue was frozen in liquid nitrogen. In the other experi-
ments, striatal slices or substantia nigra preparations
were frozen after a 1 h in vitro pre-incubation with rote-
none (10 μM). The weighed frozen tissue was homoge-
nized in an appropriate volume of ice-cold 0.1 M
perchloric acid that contained theophylline (as an inter-
nal standard) in a 10 nmol/ml concentration and 0.5
mM sodium metabisulfite (antioxidant for biogenic
amines). The suspension was centrifuged at 300 g (4500
rpm) for 10 min at 0-4°C. The excess perchlorate anion
in the supernatant was removed by the addition of 2 M
KOH in 7:3 ratios, respectively. The potassium perchlo-
rate was removed by centrifugation as described above.
The supernatant was kept at -20°C until analyzed. The
pellet was saved for protein measurement according to
Lowry et al. [62].
A Gilson liquid chromatographic System with 715-
operation software (Gilson Medical Electronics Inc.,
Middletown, WI, USA) was used. Two delivery pumps
(Model 305) and a programmable auto injector (Model
231 XL) were built in. The system was equipped with
BAS CC-4 amperometric and Agilent 1100 variable
wavelength detectors in a cascade line. For sample
cleaning, a “trap-column” (15-25 μm Nucleosil C-18 (20
× 4.0)) was inserted into a loop position. The separa-
tions were performed on a 3 μm Discovery C18 HS (150
× 4.0 mm) analytical column. For the quantification of
nucleotides and biogenic amines, a two-dimensional
reversed-phase and an ion pair chromatographic separa-
tion were used [40]. After the elution of nucleotides, an
ion pair-reversed-phase buffer at constant flow rate (0.8
ml/min) was applied from the 11th to 55th min of ana-
lysis. The detection of adenine nucleotides and internal
standards (IS) was performed at 254 nm wavelengths by
UV, and the biogenic amines were measured at a 0.73 V
potential of electrochemical detection. The retention
order of UV-detected compounds were as follows:
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diphosphate (ADP) 6.1 min, adenosine 5’-monopho-
sphate (AMP) 11.7 min and theophylline (IS) 21.2 min.
The order of monoamines were norepinephrine (NE)
14.7 min, 3,4-dihydroxyphenylacetic acid (DOPAC) 16.8
min, 5-hydroxy indolacetic acid (5-HIAA) 19.3 min,
dopamine (DA) 25.5 min, homovanillic acid (HVA) 26.8
min, 3-methoxytyramine (3-MT) 31.2 min and 5-hydro-
xytryptamine (5-HT) 39.3 min.
The separation of pre-column dansylated amino acids
and endocannabinoids was performed with a gradient
elution-working mode at ambient temperature. The
mobile phase A consisted of 5/95 (v/v) 78/22 acetoni-
trile/methanol in 15 mM ammonium formate buffer,
and the mobile phase B was composed of 90/10 (v/v 78/
22) acetonitrile/methanol in ammonium formate buffer,
pH 3.7. The mobile phase B increased linearly (at 0.11
min to 50% at 17 min 72% and at 26 min 100% and was
run to 54 min), and the flow rate was 0.7 ml/min. The
analytical and the trap column were equilibrated for 10
min, and the enrichment and clean-up procedures were
started. Dansylated derivatives were detected using an
absorbance detector (Agilent 1100) at a 319 nm wave-
length. The retention times of dansylated compounds
were as follows: aspartic acid (Asp) 10.3 min, glutamic
acid (Glu) 11.4 min, gamma amino butyric acid (GABA)
16.2 min, AEA 48.5 min and 2-AG 50.5 min. Pre-col-
umn derivatization was performed by mixing 50 μlo f
dansyl chloride (prepared by dissolving 5 mg 5-
(dimethylamino)naphthalene-1-sulfonyl chloride in acet-
onitrile daily and adding 50 μl of 2 M sodium carbonate,
which contained norvaline as an internal standard in 20
μMw i t h2 5μl of sample. After a 10-min reaction time
at 60°C, the mixture was acidified with 25 μl of 6 M for-
mic acid and injected onto the “trap-column”.
The concentrations of separated compounds were cal-
culated using a two-point calibration curve internal
standard method: (Ai * f * B)/(C * Di * E) (Ai: Area of
component; B: Sample volume; C: Injection volume; Di:
Response factor of 1 pmol of standard; E: Protein con-
tent of sample; f: factor of Internal Standard (IS area in
calibration/IS area in actual)). The data are expressed as
nmol per mg protein or as pmol per mg protein.
[
3H]Dopamine release experiments
Mice were decapitated and the brain was quickly
r e m o v e di n t oa ni c e - c o l dK r e b s ’ solution. The striatum
was dissected out and sliced into 400-μm-thick sections
with a McIlwain tissue chopper. The release experi-
ments were performed as described previously [33,41].
Briefly, the slices were pretreated with rotenone (10
μM) for 60 min and then rinsed with a normal Krebs’
solution. The slices were then incubated in 1 ml of
Krebs’ solution containing 5 μCi [
3H]DA for 45 min,
during which they were continuously gassed with a mix-
ture of 95% O2 and 5% CO2 at 37°C. After incubation,
the slices were rinsed and transferred to tissue chambers
and perfused continuously with a modified Krebs solu-
tion (in mM: NaCl 113, KCl 4.7, CaCl2 2.5, KH2PO4 1.2,
MgSO4 1.2, NaHCO3 25, Na2EDTA 0.03, ascorbic acid
0.3, and glucose 11.5) at a rate of 0.7 ml/min. After a
60-min pre-perfusion, 3-min samples were collected and
assayed for [
3H]DA.
Electrical field stimulation (EFS, S1, S2) was delivered
by a Grass S88 stimulator twice, during the 3
rd and 13
th
sample of the collection period, using platinum ring
electrodes attached to the top and bottom of tissue
chambers with the following parameters: 25 V, 1 msec,
2 Hz, 240 shocks. At the end of the experiment, the
slices were homogenized in 0.5 ml of 10% trichloroacetic
acid. A 0.5 ml aliquot of the superfusate and 0.1 ml of
the tissue supernatant were added to 2 ml of scintilla-
tion cocktail (Ultima Gold, Packard). Tritium was mea-
sured with a Packard 1900 TR liquid scintillation
counter using an internal standard and expressed as per-
centage of the amount of radioactivity in the tissue at
the time of sample collection (fractional release, FR %).
The tissue tritium uptake was determined as the sum
r e l e a s e+t h et i s s u ec o n t e n ta f t e rt h ee x p e r i m e n ta n d
expressed in Bq/g.
Materials
The following materials were used: brilliant blue G
(BBG), L-deprenyl, DMSO, Dulbecco’s Modified Eagle’s
Medium, fetal bovine serum, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), rotenone, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT), (all from Sigma-Aldrich, St. Louis, MO),
AZ10606120 dihydrochloride (Tocris Bioscience, Ellis-
ville, MO, USA). All solutions were freshly prepared on
the day of use.
Data analysis
All data are expressed as means ± S.E.M. of n observa-
tions. Statistical analyses were performed using an
ANOVA followed by the Dunnett test (multiple com-
parisons) or Student’s t-test (pair-wise comparisons).
The log-rank test was used for the statistical evaluation
of survival data. Graphpad Prism software was used for
all statistical analyses. P values of less than 0.05 were
considered statistically significant.
Adenylate energy charge (EC), introduced by Atkinson
[63], was calculated accordingly:
EC = ([ATP] + 0.5[ADP])/([ATP] + [ADP] + [AMP]
The EC value represents the energy resources of a cell
as a function of the concentration of nucleotides. A
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over other adenine nucleotides, and the corresponding
EC is close to one.
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